How to Sell a Hospice Business (2026): Selling a Hospice With Multiples, Named Buyers, & Operator Playbook

Selling a hospice in 2026 comes down to three things buyers test before they talk price: clean Medicare compliance, a census that is growing, and an ownership history that clears the CMS 36-month rule. This guide covers how to sell a hospice business: what hospice businesses sell for, who is buying, the regulatory traps that stall deals, and the operator playbook for getting ready well before you go to market.

Quick Answer

Christoph Totter · Managing Partner, CT Acquisitions

M&A advisory across 500+ active capital partners · Senior services M&A: hospice, home health, palliative care · Updated June 6, 2026

A US hospice business in 2026 typically sells for roughly 4x to 11x EBITDA, varying by census size, payer mix (Medicare is dominant in hospice, ~90%+ typical), regulatory compliance, and platform scale. By profile: a single-site hospice with low census ($500k-1.5M EBITDA) goes 4x-6x EBITDA; a multi-site hospice group ($1.5-4M EBITDA, multi-state or single-state-with-density) goes 5x-7x EBITDA; a regional hospice platform ($4-12M EBITDA, multi-state, diversified census) goes 6x-9x EBITDA; a premium scale hospice platform ($12M+ EBITDA, multi-state with strong CMS hospice quality reporting program [HQRP] scores, integrated palliative care, modern operating system) reaches 8x-11x+ EBITDA. The major regulatory consideration is the OIG / DOJ focus on hospice fraud (routine recerts, GIP/general inpatient billing, length-of-stay outliers, F/G/H tags) which materially impacts diligence depth. Active buyers include Addus HomeCare (NASDAQ: ADUS, ~$1B+ revenue, the largest US public home-care + hospice consolidator), Compassus (PE-backed, multi-state hospice + palliative care + home health), BrightSpring Health Services (NASDAQ: BTSG, hospice through home health segment), VITAS Healthcare (Chemed Corp NYSE: CHE subsidiary, the largest US dedicated for-profit hospice with ~$1.5B+ revenue), AccentCare (Advent International, home health + hospice + personal care), Aveanna Healthcare (NASDAQ: AVAH, hospice segment), Empath Health (Florida-based non-profit), Three Oaks Hospice (PE-backed), Heartland Hospice (HCR ManorCare), plus PE sponsors (Advent International, Webster Equity Partners, Bain Capital, Linden Capital, plus multiple healthcare-services PE funds). Note: UnitedHealth Group/Optum completed its acquisition of Amedisys on August 14, 2025, after a DOJ settlement that required 164 home health and hospice divestitures (Healthcare Dive). The biggest multiple drivers are CMS HQRP scores, average daily census (ADC), payer mix and length-of-stay distribution, modern EMR (Hospicelink, Suncoast, Homecare Homebase, MatrixCare), and compliance posture (clean OIG/DOJ history). No fee to you on buy-side introductions; sell-side mandates are paid on success at closing.

If you own a hospice business in 2026, the M&A market is active and capital-deep. Addus HomeCare (NASDAQ: ADUS) is the largest US public home-care+hospice consolidator. Compassus (PE-backed) operates a multi-state hospice + palliative + home health platform. BrightSpring Health Services (NASDAQ: BTSG) operates hospice through its home health segment. VITAS Healthcare (Chemed Corp) is the largest US dedicated for-profit hospice. Amedisys is now part of UnitedHealth Group/Optum, which closed the acquisition on August 14, 2025 (Healthcare Dive). PE sponsors (Advent International, Webster Equity Partners, Bain Capital, Linden Capital) continue rolling up regional hospices.

What the asset is worth depends on three things: (1) CMS HQRP (Hospice Quality Reporting Program) scores and survey history (a clean recent CMS survey is a multiple-builder; F-tag deficiencies or condition-level findings are deal-killers), (2) census size and payer mix (90%+ Medicare is typical; length-of-stay distribution and routine-recert audit history matter), and (3) compliance posture (OIG / DOJ scrutiny on hospice fraud is high). This guide covers real multiples by profile, the named buyers transacting, and the operator-level diligence buyers will run.

Named hospice M&A transactions (2022-2025)

No fee to you on buy-side introductions; sell-side mandates are paid on success at closing.

The named buyer landscape

Public / strategic buyers

• VITAS Healthcare (Chemed Corp NYSE: CHE subsidiary), ~$1.5B+ revenue, the largest US dedicated for-profit hospice.
• Amedisys, $2.3B+ revenue, part of UnitedHealth Group/Optum since the acquisition closed on August 14, 2025 (Healthcare Dive).
• Addus HomeCare (NASDAQ: ADUS), ~$1.1B+ revenue, the largest US public home-care + hospice consolidator.
• BrightSpring Health Services (NASDAQ: BTSG), $8.5B+ total revenue (hospice is one segment), IPO’d Jan 2024.
• Aveanna Healthcare (NASDAQ: AVAH), $2.1B+ revenue with hospice segment.

PE-backed national platforms

• Compassus (PE-backed), multi-state hospice + palliative + home health platform.
• AccentCare (Advent International), home health + hospice + personal care.
• Three Oaks Hospice (PE-backed), multi-state hospice.
• Empath Health (Florida-based, non-profit), large regional.
• Heartland Hospice (HCR ManorCare).

PE sponsors active in this space

• Advent International (AccentCare), Webster Equity Partners, Bain Capital, Linden Capital, plus multiple healthcare-services PE funds.

What each buyer will pay for vs. what they reject

• Will pay premium for: strong CMS HQRP scores (the publicly-reported quality benchmark), clean OIG/DOJ compliance history with no open matters, multi-state licensure, average daily census growth, integrated palliative care + home health, modern EMR (Hospicelink, Suncoast, Homecare Homebase, MatrixCare), strong nurse and chaplain bench depth, documented bereavement program quality, normal Medicare length-of-stay distribution (not outlier-dependent).
• Will compress or reject: F-tag deficiencies or condition-level CMS survey findings, OIG/DOJ investigation history, length-of-stay-outlier dependency (especially routine recert issues), weak HQRP scores, owner-clinician dependence, single-state without expansion path, legacy EMR, undocumented GIP (general inpatient) billing patterns.

The 36-month rule and other CMS rules that shape selling a hospice

Hospice is one of the few businesses where a federal rule can stop a sale outright. Effective January 1, 2024, CMS extended its 36-month rule to hospices, per Greenberg Traurig. The rule bars a change in majority ownership, meaning more than 50% of the direct ownership interests (Greenberg Traurig), within 36 months of the hospice’s Medicare enrollment or its last change in majority ownership. It covers asset purchases, stock transfers and mergers alike. If it applies, the Medicare provider agreement and billing privileges do not transfer to the buyer.

What that means in practice:

• Check your clock first. If your hospice was enrolled in Medicare or changed majority ownership in the last three years, most buyers will wait or walk, because without the provider agreement they are buying a business that cannot bill Medicare.
• Exceptions are narrow. Internal restructurings and a few other cases can qualify, but Mertz Taggart notes the exceptions are narrow and fact-specific. Have healthcare counsel confirm your position before you go to market.
• New licenses are harder to get. Mertz Taggart reports that CMS announced a nationwide moratorium on new Medicare enrollments for home health and hospice providers in May 2026, for an initial six-month period. Buyers who cannot start a new hospice have more reason to buy an existing, compliant one.
• State approval still applies. Some states require a certificate of need or prior approval of a license transfer for hospices, which adds weeks to the closing timeline.

The practical step is simple: before you take a call from a buyer, pull your Medicare enrollment record and ownership history, and list every transaction or ownership change since your last enrollment. A buyer’s counsel will ask for it in the first week of diligence.

The operator-level KPI playbook buyers will diligence

Census and clinical metrics

• Average daily census (ADC): The primary scale metric. Track by site.
• Admission rate: Patients admitted per month.
• Median and average length of stay (LOS): Watch for outlier dependency.
• LOS distribution: Document percentage of patients in 0-7 days, 8-30 days, 31-180 days, 181-365 days, 365+ days.
• Discharge mix: Death, live discharge, transfer, recert-driven.

Payer mix

• Medicare percentage: 90%+ Medicare is typical (Medicare Hospice Benefit dominates the industry).
• Medicare Advantage hospice carve-in: Track participation in the CMS Hospice Carve-In demonstration model where applicable.
• Medicaid hospice: Limited; varies by state.
• Commercial hospice: Limited; track if present.

CMS compliance and quality

• HQRP scores: Hospice Quality Reporting Program publicly-reported quality measures. Document scores by measure.
• Hospice CAHPS scores: Hospice Consumer Assessment of Healthcare Providers and Systems patient/family survey scores.
• CMS survey history: 3-5 year survey history, documented; F-tags resolved.
• HOPE (Hospice Outcomes & Patient Evaluation) data quality.

OIG / DOJ compliance

• Open investigations: Any OIG, DOJ, MFCU, state-AG investigation must be disclosed.
• Recert documentation: 1st recert at 90 days, 2nd recert at 180 days, third+ at 60 days; documentation must support continued eligibility.
• GIP (general inpatient) billing patterns: Document GIP days per patient, GIP triggering criteria, and chart documentation.
• Routine recert audit defense: Documented internal-audit cycles.

Workforce

• RN, hospice aide, social worker, chaplain headcount and ratios.
• Hospice physician medical director.
• Bereavement program: 13-month minimum required by CMS.
• Volunteer program: 5%+ of patient care hours required by CMS.

Operating system and technology

• EMR: Hospicelink (Net Health), Suncoast (Complia Health), Homecare Homebase, MatrixCare, Axxess Hospice, ClearCare.
• Mobile clinician documentation.
• Bereavement and volunteer tracking.

Dangers and traps in hospice M&A

1. OIG / DOJ scrutiny on hospice fraud

Hospice fraud (routine recerts without medical necessity, GIP billing without supporting criteria, length-of-stay outlier dependency) is an OIG/DOJ enforcement priority. Any open investigation is a binary “walk” risk for most buyers.

2. F-tag deficiencies on CMS survey

Condition-level F-tags or recent survey deficiencies must be resolved. Buyer-side diligence will pull CMS survey history.

3. Length-of-stay outlier dependency

If your revenue depends on long-LOS patients (365+ days at routine home care rate), that is recert audit risk. Document recert chart support carefully.

4. GIP (general inpatient) billing patterns

GIP is a higher reimbursement category. Buyers will audit GIP triggering criteria and chart documentation; over-utilization is OIG/DOJ red flag.

5. Owner-clinician dependence

If the owner is the medical director or lead RN with personal patient relationships, build the clinical bench.

6. Single-state without expansion path

Multi-state platforms command premium multiples. Single-state operators with no documented expansion plan compress.

7. Aggregate cap exposure

Medicare hospice has an aggregate cap (per-patient lifetime cap). If your operation has cap issues, document and resolve.

8. Legacy EMR and documentation hygiene

Modern EMR (Hospicelink, Suncoast, Homecare Homebase, MatrixCare) supports the audit-defense documentation buyers require.

Our POV on hospice M&A in 2026

• Single-site low-census hospices ($500k-1.5M EBITDA) go 4x-6x EBITDA.
• Multi-site or single-state-density hospices ($1.5-4M EBITDA) go 5x-7x.
• Regional multi-state platforms ($4-12M EBITDA) go 6x-9x.
• Premium scale platforms ($12M+ EBITDA, multi-state, strong CMS HQRP, clean compliance, integrated palliative) reach 8x-11x+.

The right time to prepare is 12-18 months before going to market, address any open OIG/DOJ matters, document CMS HQRP performance, audit recert documentation, modernize EMR, develop clinical leadership bench, and confirm aggregate cap compliance.

Preparing your hospice business for sale: 12-18 months out

To sell a hospice, start 12 to 18 months ahead: confirm your Medicare enrollment and ownership history clear the CMS 36-month rule, resolve any open audits, document census growth and quality scores, and get reviewed financials. Then run a confidential process to strategic and PE-backed buyers, with regulatory diligence built into the timeline.

1. Get multi-year audited or reviewed financials.
2. Resolve any open OIG/DOJ matters. Disclose resolved matters with full documentation.
3. Document CMS HQRP performance and survey history.
4. Audit recert documentation. Internal-audit cycles for routine recerts and GIP billing.
5. Confirm aggregate cap compliance.
6. Modernize the EMR. Hospicelink, Suncoast, Homecare Homebase, MatrixCare.
7. Develop the clinical leadership bench. Medical director, clinical director, RN supervisors.
8. Document bereavement and volunteer program compliance.
9. Run a competitive process. VITAS (Chemed), Addus HomeCare, Compassus, BrightSpring, AccentCare (Advent), Aveanna, Three Oaks Hospice, plus PE sponsors directly (Advent International, Webster Equity, Bain Capital, Linden Capital).

The five pillars of how CT Acquisitions works

Frequently asked questions

What is the typical multiple for a hospice business in 2026?

Single-site low-census hospices ($500k-1.5M EBITDA) typically sell at 4x-6x EBITDA. Multi-site or single-state-density hospices ($1.5-4M EBITDA) go 5x-7x. Regional multi-state platforms ($4-12M EBITDA) go 6x-9x. Premium scale platforms ($12M+ EBITDA, multi-state, strong CMS HQRP scores, clean OIG/DOJ compliance, integrated palliative care) reach 8x-11x+.

Who are the active buyers of hospice businesses right now?

Public/strategic: VITAS Healthcare (Chemed Corp NYSE: CHE, ~$1.5B+ revenue), Amedisys (part of UnitedHealth Group/Optum since August 2025), Addus HomeCare (NASDAQ: ADUS), BrightSpring Health Services (NASDAQ: BTSG), Aveanna Healthcare (NASDAQ: AVAH). PE-backed: Compassus, AccentCare (Advent International), Three Oaks Hospice. Non-profit: Empath Health. PE sponsors: Advent International, Webster Equity Partners, Bain Capital, Linden Capital.

What hurts a hospice business’s valuation most?

Open OIG/DOJ investigations or unresolved matters, condition-level F-tag deficiencies on CMS survey, length-of-stay outlier dependency (especially 365+ day patients without strong recert documentation), GIP billing pattern issues, weak HQRP scores, owner-clinician dependence, single-state operations without expansion path, legacy EMR, and aggregate-cap exposure.

What is the Medicare Hospice Aggregate Cap and why does it matter?

The Medicare hospice aggregate cap is an annual, provider-level limit on total Medicare hospice payments: CMS sets a per-beneficiary cap amount each fiscal year, and a hospice’s limit equals that amount times its number of Medicare beneficiaries. Hospices with high cap utilization may face payment recoupments, and buyers will scrutinize cap exposure carefully. Cap utilization above 90% is a diligence concern.

Why is OIG/DOJ scrutiny so high in hospice?

Hospice fraud (routine recertification without medical necessity, GIP billing without supporting criteria, length-of-stay outlier dependency) has been a documented OIG/DOJ enforcement priority. Settlements in the hospice sector have been large and public. Any open investigation is a binary ‘walk’ risk for most buyers, and even resolved matters require full disclosure and documentation.

Do I have to pay a broker fee?

It depends on the mandate. CT Strategic Partners works both sides of the table and is not a business broker. When a buyer from our network approaches you through a buy-side search, you pay no fee; when you hire us to run a sell-side process, we are paid on success at closing, with terms agreed in writing before any work starts.

How long does it take to sell a hospice business?

Once you go to market with an M&A advisor, a typical process runs 6-9 months from initial outreach to closing, with regulatory diligence extending the timeline. Add 12-18 months of preparation work before going to market.

When should I start preparing if I plan to sell in 2027 or 2028?

12-18 months before going to market is the right window. Highest-leverage pre-sale work: resolve any open OIG/DOJ matters, document CMS HQRP performance, audit recert and GIP documentation, modernize EMR, develop clinical leadership bench, and confirm aggregate cap compliance.

What is the 36-month rule for hospice?

It is a CMS rule, extended to hospices effective January 1, 2024 per Greenberg Traurig, that blocks a change in majority ownership within 36 months of a hospice’s Medicare enrollment or its last change in majority ownership. If a sale breaks the rule, the Medicare provider agreement and billing privileges do not transfer to the buyer, so most buyers will not close until the 36 months have passed.

Why do buyers acquire existing hospices instead of starting new ones?

A new hospice needs state licensing, Medicare enrollment and time to build referral relationships, and the 36-month rule limits flipping new agencies. With CMS adding a moratorium on new home health and hospice enrollments in May 2026, buying an established, compliant hospice with a Medicare provider agreement is often the faster path for buyers who want to enter a market.

Related research

• How to sell a home care business
• How to sell a home health agency
• How to sell an infusion therapy business
• How to sell a DME business
• How to sell an urgent care center
• How to sell a physical therapy practice
• Healthcare business valuation
• Which industries is PE buying most in 2026
• Private equity value creation
• Business broker alternative

About the Author

Owners weighing DIY versus full-service representation should read our sell-side fee math.

Christoph Totter is the founder of CT Acquisitions, an M&A advisory firm working both sides of the table, headquartered in Sheridan, Wyoming. We work directly with 500+ buyers, search funders, family offices, lower middle-market PE, and strategic consolidators, including direct mandates with the largest home services consolidators that other intermediaries can’t access. No fee to you on buy-side introductions; sell-side mandates are paid on success at closing. Connect on LinkedIn · Get in touch